An angel group based in the Midwest invests up to $200K per company in early stage opportunities. The group usually invests in 9-12 companies per year and participates in convertible rounds, as well as equity investments. The Group is not restricted to Midwest companies, as it will also consider companies throughout the U.S. As membership grows, the group expects the average investment number to increase.

The group is open to all types of life science technology including Therapeutics, Healthcare IT, medical devices, and platform technologies. The group is also indication agnostic. In medical devices, the group is only interested in those in the 510K approval pathway. In terms of stage of development, the group is interested in pre-clinical to Phase I technologies.

The group is interested in companies seeking between $500K to $3M. The group does not have management team requirements though has preference towards those with experience in the space.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in North Carolina is investing from a fund with over $170 million in available capital. The fund focuses on seed-stage life science companies. The firm typically invests between $2 and $4 million initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes. The firm is looking to make 4-6 allocations in the next 6-9 months throughout the United States, with an emphasis on leading company formations in the Southeast.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Device and Healthcare IT spaces. In the Therapeutics space, the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics, the firm is looking for companies primarily with a lead product in preclinical trials, although they will consider companies with products having recently entered Phase I. In the Medical Device space, the firm strongly prefers that the company at least has an early prototype of their product and the firm is opportunistic in terms of medical device subsector and is open to all classes of device. For Healthcare IT investments, the firm looks only at post-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based venture fund that invests only in seed and pre-seed rounds is focusing on opportunities in the healthcare sector. The firm will consider opportunities US-wide, with a particular interest in Texas, California and the Northeast.

The firm invests in very early stage companies across the healthcare innovation ecosystem, including pharma, medical devices, diagnostics, and healthcare IT. The firm is highly interested in preventative healthcare, including technologies that could prevent allergies and asthma; other areas of interest include EMR, bioinformatics, and value-based care. The firm is open to investing in any area of medicine, and has an interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health.

The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a good track record in their sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment vehicle founded by a regional government agency in China focuses on scientific research, technology transfer, and commercialization. The firm is seeking new life science technologies through investment, licensing, or research collaboration. The firm can make equity investment of up to RMB 10M (US$1.5M) from its two funds of RMB 100M (US$15M) each. The firm is currently looking for China-based opportunities and overseas teams that are Chinese-led or have representatives in China.

The firm considers across several sectors including therapeutics, medical devices, diagnostics, and digital health. Within therapeutics, the firm is interested in cancer immunotherapy and infectious diseases. The firm is also interested in Anesthesia consumables, IVF related technologies and devices, orthopedic devices, wound and trauma care (within medical devices), IVD (within diagnostics), and artificial intelligence (within digital health). The firm is seeking products that have obtained or are close to obtaining FDA approval/clearance. The firm aims to advance the project through development milestones and CFDA registration process in China.

The firm is looking for Chinese-led teams or companies that have representatives in China. In addition to financial investment, the firm can also provide incubation space and R&D support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Toronto, Canada with an additional office in the USA invests in early stage start-ups across several industries including healthcare. The firm typically invests US$50-250K in seed-stage companies, while Series A or B may also be considered. The firm only follows in a financing round. The firm is currently looking for opportunities from North America.

Within healthcare, the firm takes an opportunistic approach and considers across medical devices, diagnostics, and healthcare IT. The firm is agnostic to disease indications. The firm prefers revenue-generating companies, while pre-revenue companies could also be considered. The firm will also consider some therapeutics opportunities depending on the lead.

The firm is looking for teams with a good mixture of technical expertise and business experience. The firm takes an active approach post-investment and seeks to work with passionate, talented entrepreneurs with strong academic track records.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com

A venture capital firm with investment teams in the USA and Switzerland is currently investing out of their second fund, and looks to invest in early-stage life science companies crossing all sectors. The firm focuses on Seed, Series A and Series B investments. Investment is in the form of equity with the firm making roughly 3-5 new investments per year. The firm typically invests $500K – $5M per round (depending on the stage and needs of the company), and generally invests $10-$15M throughout the life of a company. The firm is very comfortable leading investment rounds, and focuses on companies in the US and Europe.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, tools and medical device sectors. The firm is opportunistic in terms of sub-sectors and indications. The firm is only interested in preclinical/Phase I, early-stage technology. The firm looks for companies with proprietary technologies that allow them to address unmet needs in a unique and compelling manner. The firm is not interested in healthcare IT, healthcare services or software companies.

The firm invests in privately-held companies with passionate founders and/or a strong management team. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com

A firm focused on innovation innovation and entrepreneurship in healthcare works with dozens of leading healthcare organizations to advance an innovation strategy in order to drive sustainable impact. The firm manages a $35 million fund focused on health technologies with a provider angle. Typical size of an initial investment is $1-3 million in Seed to Series B round. The firm can invest up to $5 million over the lifetime of a company. The firm is open to leading or syndicating in a financing round. The firm is currently seeking opportunities globally, but currently has a focus in the U.S.

The firm considers HealthTech innovations that have a strategic angle to healthcare providers and do not need to go through regulatory development hurdle. Examples may include healthcare operational improvement, healthcare workflow management, data analytics, radiologic information analysis, telemedicine, population management, and automated screening. The firm is interested in the diseases that affect large populations such as oncology, cardiovascular diseases and stroke, hypertension, and geriatric conditions. The firm does consider devices if they are past the regulatory hurdle and can be applied to a large health system.

The firm is looking for competent management teams developing innovative solutions to real-world problems in the healthcare industry. The firm’s limited partner is actively involved in the vetting process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com